Prana Biotechnology Limited leaps on potential breakthrough: Should you buy?

What: Shares in biotech business Prana Biotechnology Limited (ASX: PBT) rocketed more than 42% today after it announced that its PBT2 drug for the treatment of Huntington’s disease has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA).

So what: Orphan drug designation is granted by the FDA to promote the development of drugs for rare diseases that affect less than 200,000 people in the U.S.

Huntington’s disease is a neurodegenerative brain disorder that leads to cognitive decline. It affects more than 30,000 people in the U.S. and there are currently no effective treatments for the cognitive decline symptoms of the disease.

The company plans to apply for Orphan Drug designation in other jurisdictions.

Now what: Orphan Drug designation entitles Prana to seven years of market exclusivity for the use of PBT2 in the treatment of Huntington’s disease. It also means Prana is able to formally receive guidance from the FDA as to how to go about the approval process in applying for eventual marketing approval.

Prana recently completed a Phase 2 trial of the drug’s effectiveness in treating Huntington’s disease. Prana says some of the trial results were positive in showing statistically significant behavioural improvement in some of the patients using the drug.

The company says it is now developing its Phase 2 trial dossier for submission to the FDA to commence discussions on the next development steps for PBT2. Notably, Prana remains a long way off being able to commercialise the drugs and its biggest problem remains demonstrating to the FDA that they are actually effective in the treatment of Huntington’s.

Back in February shares in Prana lifted to more than $1.30 as a whirl of publicity-driven excitement surrounded the company’s claims that it had a real chance of developing the PBT2 drug as a treatment for Alzheimer’s disease. However, when trial results disappointed shares crashed around 80% to under 20 cents as the old investing adage of buy the rumour sell the fact came home to roost.

Investors appear to be throwing more caution to the wind on the latest news and Prana remains a highly speculative play.

There's no need to chase speculative biotechs if you're looking to make big returns. Why not just buy junior companies selling in demand products like oil, copper and nickel?

Luckily, The Motley Fool has uncovered three companies poised to benefit from the rising prices of these commodities. Get our brand-new report -- "3 'Under-the-Radar' Resources Companies That Could Win Big" -- FREE!

Motley Fool contributor Tom Richardson has no financial interest in any company mentioned. You can find him on Twitter @tommyr345

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.